{
    "Case ID": "067658",
    "Crime_Name": [
        "Patent Infringement Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Infringement Dispute"
    ],
    "Legal_Issue": [
        "Validity of the '784 Patent based on utility and obviousness-type double patenting"
    ],
    "Governing_Law": [
        "Canadian Patent Law"
    ],
    "Procedural_Stage": [
        "Pre-trial injunction phase / Application for prohibition order"
    ],
    "Evidence_Assessment": [
        "Expert testimony, prior art, patent claims analysis"
    ],
    "Decision_Outcome": [
        "'784 Patent upheld as valid"
    ],
    "Burden_of_Proof": [
        "On Mylan to prove invalidity"
    ],
    "Credibility_Factor": [
        "Expert testimony supporting sound prediction of utility"
    ],
    "Legal_Rule": [
        "Utility must be demonstrated or soundly predicted at filing date; Obviousness-type double patenting requires lack of novelty or ingenuity over earlier patent"
    ],
    "Standard_of_Review": [
        "Not explicitly stated, but implied as correctness for legal issues and reasonableness for factual inferences"
    ],
    "Procedural_Issue": [
        "Application to prohibit regulatory approval before patent expiry"
    ],
    "Grounds_for_Claim": [
        "Lack of utility, obviousness-type double patenting"
    ],
    "Outcome_on_Merits": [
        "Claim of invalidity rejected; patent found valid"
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [
        "Patent validity upheld"
    ],
    "Review_Standard": [
        "Assessment of legal interpretation and evidentiary support"
    ],
    "Procedural_Fairness_Assessment": [
        "Parties had opportunity to present evidence and argument"
    ],
    "Key_Evidence_Considered": [
        "Prior art disclosing tadalafil as PDE V inhibitor, expert testimony on sound prediction, comparison between '784 and '377 Patents"
    ],
    "Legal_Framework": [
        "Canadian Patent Act and jurisprudence on utility and double patenting"
    ],
    "Applicant_Challenge": [
        "Mylan challenged validity to obtain regulatory approval for generic tadalafil"
    ],
    "Court_Result": [
        "Order granted prohibiting Mylan from receiving regulatory approval until patent expiration"
    ],
    "Legal_Rule_Source": [
        "Canadian Patent Law"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Mylan alleged lack of utility and obviousness-type double patenting"
    ],
    "Evidence_Type": [
        "Documentary evidence (patents), expert opinion"
    ],
    "Remedy_Requested": [
        "Order prohibiting Mylan from obtaining regulatory approval"
    ],
    "Outcome": [
        "Remedy granted; Mylan barred until patent expiry"
    ],
    "Decision_Authority": [
        "Trial Court"
    ],
    "Remedy_Sought": [
        "Injunction against regulatory approval"
    ],
    "Resolution_Mechanism": [
        "Judicial determination on application for interim relief"
    ],
    "Legal_Provision": [
        "Provisions related to patent validity, utility, and double patenting under Canadian law"
    ],
    "Authority": [
        "Canadian courts"
    ],
    "Claimant_Status": [
        "Eli Lilly as patent holder"
    ],
    "Legal_Provision_Cited": [
        "Canadian Patent Law on utility and obviousness-type double patenting"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Lack of utility, obviousness-type double patenting"
    ],
    "Applicable_Process": [
        "Regulatory approval process under patent linkage regime"
    ],
    "Outcome_of_Review": [
        "Invalidity challenge dismissed"
    ],
    "Pending_Relief_or_Application": [
        "Application for prohibition order pending resolution of patent validity"
    ],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Utility and non-obviousness requirements for patent validity; prohibition on generic approval during patent term"
    ]
}